# Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

> **NCT02171325** · PHASE2 · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 54 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT02171325
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2021-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171325, "Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02171325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*